These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients. O'Hare F; Jeganathan VS; Rokahr CG; Rogers SL; Crowston JG Clin Exp Ophthalmol; 2009 Dec; 37(9):849-54. PubMed ID: 20092593 [TBL] [Abstract][Full Text] [Related]
26. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Chang DS; Friedman DS; Frazier T; Plyler R; Boland MV Ophthalmology; 2013 Jul; 120(7):1396-402. PubMed ID: 23541760 [TBL] [Abstract][Full Text] [Related]
27. A clinician's guide to the assessment and management of nonadherence in glaucoma. Budenz DL Ophthalmology; 2009 Nov; 116(11 Suppl):S43-7. PubMed ID: 19837260 [TBL] [Abstract][Full Text] [Related]
29. A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects. Kawai-Tsuboi N; Kawai M; Minami Y; Yoshida A J Glaucoma; 2015 Mar; 24(3):202-6. PubMed ID: 23807351 [TBL] [Abstract][Full Text] [Related]
30. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302 [TBL] [Abstract][Full Text] [Related]
31. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives. Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335 [TBL] [Abstract][Full Text] [Related]
32. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Erb C; Lanzl I; Seidova SF; Kimmich F Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844 [TBL] [Abstract][Full Text] [Related]
33. Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy. Roberti G; Agnifili L; Berardo F; Riva I; Figus M; Manni G; Quaranta L; Oddone F Adv Ther; 2018 May; 35(5):686-696. PubMed ID: 29687335 [TBL] [Abstract][Full Text] [Related]
34. Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Olthoff CM; Hoevenaars JG; van den Borne BW; Webers CA; Schouten JS Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):235-43. PubMed ID: 18802720 [TBL] [Abstract][Full Text] [Related]
35. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride. Wong TT; Aung T; Ho CL Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759 [TBL] [Abstract][Full Text] [Related]
36. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent]. Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477 [TBL] [Abstract][Full Text] [Related]
37. Treatment for glaucoma: adherence by the elderly. Gurwitz JH; Glynn RJ; Monane M; Everitt DE; Gilden D; Smith N; Avorn J Am J Public Health; 1993 May; 83(5):711-6. PubMed ID: 8484454 [TBL] [Abstract][Full Text] [Related]
38. How ocular surface disease impacts the glaucoma treatment outcome. Kaštelan S; Tomić M; Metež Soldo K; Salopek-Rabatić J Biomed Res Int; 2013; 2013():696328. PubMed ID: 24224176 [TBL] [Abstract][Full Text] [Related]
39. How glaucoma patient characteristics, self-efficacy and patient-provider communication are associated with eye drop technique. Sayner R; Carpenter DM; Robin AL; Blalock SJ; Muir KW; Vitko M; Hartnett ME; Lawrence SD; Giangiacomo AL; Tudor G; Goldsmith JA; Sleath B Int J Pharm Pract; 2016 Apr; 24(2):78-85. PubMed ID: 26303667 [TBL] [Abstract][Full Text] [Related]
40. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Hommer A; Mohammed Ramez O; Burchert M; Kimmich F Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]